These drugs are collectively known as GLP-1 agonists because they mimic the body’s natural hormone GLP-1, which regulates appetite and digestion. The medications control blood sugar and help people ...

Fullerton also made tirzepatide, which is intended to mimic weight-loss and diabetes drugs Zepbound and Mounjaro. The FDA ...

Eli Lilly's blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro posted weaker-than-expected sales for the ...

The pharmaceutical giant is expected to garner $12.1 billion in sales and $1.45 in adjusted earnings per share, per the ...

The drugmaker hopes to show CagriSema leads to at least 25% weight loss, without increased side effects. Its lead in a ...

Eli Lilly has amassed a market value nearing a trillion dollars based on the assumption that demand for its new weight-loss ...

Lilly CEO Dave Ricks in Wednesday’s third-quarter earnings call acknowledged that the company is at the mercy of wholesaler ...

Some patients fear tirzepatide, sold by Eli Lilly under the brand names Zepbound and Mounjaro, will be hard to get and prohibitively expensive once compounding pharmacies are no longer producing it.

Lilly's Q3 revenue and earnings miss primarily stemmed from lower-than-expected sales of Mounjaro and Zepbound. Should ...

Both Ozempic and Mounjaro are approved by the FDA to treat Type 2 diabetes, but some doctors prescribe the medication ...

As weight-loss injections emerge as key players in the government’s anti-obesity strategy, Emma Loffhagen goes inside the ...

A staggering 64% of adults in England are classed as either overweight or obese according to the most recent NHS figures. And ...